NCT00089492View on ClinicalTrials.gov

A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
HIV Infections
Interventions
DRUG

Optimized Background ARVs

As prescribed

DRUG

enfuvirtide [Fuzeon]

180mg sc once daily for 48 weeks

DRUG

enfuvirtide [Fuzeon]

90mg sc bid for 48 weeks

Trial Locations (27)

12208

Albany

19102

Philadelphia

19107

Philadelphia

30308

Atlanta

32803

Orlando

33136

Miami

33169

North Miami Beach

34209

Bradenton

34239

Sarasota

36201

Hobson City

70112

New Orleans

77030

Houston

78705

Austin

80262

Denver

90022

Los Angeles

90048

Los Angeles

92708

Fountain Valley

02118

Boston

48202-2689

Detroit

07083

Union

18102-7017

Allentown

M5G 2C4

Toronto

H2X 2P4

Montreal

H3G 1A4

Montreal

00732

Ponce

00921-3201

San Juan

00935

San Juan

Sponsors

Collaborators (1)

Trimeris
All Listed Sponsors
collaborator

Trimeris

INDUSTRY

lead

Hoffmann-La Roche

INDUSTRY

NCT00089492 - A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients | Biotech Hunter | Biotech Hunter